Search for content, post, videos

Update on AstraZeneca’s STORM CHASER trial

The company has announced results from a trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The trial did not meet the primary endpoint of post-exposure
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.